BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026)
BridgeBio Pharma (BBIO) posted Capital Expenditures of $69000.0 for Q1 2026, down 93.64% sequentially from $1.1 million in Q4 2025.
BridgeBio Pharma (BBIO) Capital Expenditures (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Capital Expenditures for 9 years, with the latest figure at $69000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 380.29% YoY) and the FY2025 annual result came in at $1.1 million, up 293.19% from the prior year.
- Capital Expenditures slipped to $69000.0 in Q1 2026 per BBIO's latest filing, from $1.1 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $4.8 million in Q4 2022 and troughed at -$3.2 million in Q3 2022.
- A 5-year average of $424400.0 and a median of $69000.0 in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 246.03% in 2024, then soared 21600.0% in 2025.
- Over 5 years, Capital Expenditures stood at $4.8 million in 2022, then tumbled by 101.93% to -$92000.0 in 2023, then surged by 105.43% to $5000.0 in 2024, then jumped by 21600.0% to $1.1 million in 2025, then tumbled by 93.64% to $69000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $69000.0, $1.1 million, and $12000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 443,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 443,000.00 |
| Jun 30, 2026 | 443,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Mar 31, 2026 | 69,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 204,000.00 |
| Sep 30, 2024 | 204,000.00 |
| Jun 30, 2024 | -625,000.00 |
| Jun 30, 2024 | -625,000.00 |
| Mar 31, 2024 | 695,000.00 |
| Mar 31, 2024 | 695,000.00 |
| Dec 31, 2023 | -92,000.00 |
| Dec 31, 2023 | -92,000.00 |
| Sep 30, 2023 | -248,000.00 |
| Sep 30, 2023 | -248,000.00 |